Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies

The application of anti-inflammatory therapies began thousands of years ago with the use of readily available natural resources. It is only recently, however, that the cellular and molecular mechanisms of inflammation have been appreciated sufficiently to design anti-inflammatory strategies with lim...

Full description

Saved in:
Bibliographic Details
Published in:Molecular interventions 2002-02, Vol.2 (1), p.22-35
Main Authors: D'Acquisto, Fulvio, May, Michael J, Ghosh, Sankar
Format: Article
Language:English
Subjects:
Anti-Inflammatory Agents - pharmacology
Humans
Inflammation - drug therapy
NF-kappa B - antagonists & inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The application of anti-inflammatory therapies began thousands of years ago with the use of readily available natural resources. It is only recently, however, that the cellular and molecular mechanisms of inflammation have been appreciated sufficiently to design anti-inflammatory strategies with limited side effects. For example, salicylates and glucocorticoids, two widely used anti-inflammatory drug classes, are now known to inhibit the activation of NF-kappa B, a transcription factor that regulates the inducible expression of a wide range of proinflammatory mediators. New generations of NF-kappa B-targeting anti-inflammatory agents that are specific, efficacious, and cost-effective may therefore complement or replace current therapies. In this review, we describe various classes of NF-kappa B inhibitors and discuss important unresolved issues regarding their use.
ISSN:1534-0384
1543-2548
DOI:10.1124/mi.2.1.22